Mirum Pharmaceuticals, Inc. (MIRM)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.81-0.64 (-3.44%)
As of 1:17PM EDT. Market open.
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 18.44 |
| Open | 18.42 |
| Bid | 17.57 x 1100 |
| Ask | 17.77 x 1100 |
| Day's Range | 17.58 - 18.53 |
| 52 Week Range | 12.55 - 27.43 |
| Volume | 31,201 |
| Avg. Volume | 148,073 |
| Market Cap | 538.249M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -9.33 |
| Earnings Date | Mar 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 50.29 |
- Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Business Wire
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
Mirum and Vivet Enter into Exclusive Worldwide Option and License Agreement for Gene Therapy Programs Targeting PFIC
- Business Wire
Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Review for Maralixibat in Alagille Syndrome
Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Review for Maralixibat in Alagille Syndrome
© 2021 Verizon Media. All rights reserved.
